Skip to content

A clinical study of YiyiFuziBaijiang Powder in preventing recurrence of progressive colorectal adenoma

A clinical study of YiyiFuziBaijiang Powder in preventing recurrence of progressive colorectal adenoma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080026
Enrollment
Unknown
Registered
2024-01-18
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma of the colon

Interventions

Experimental group:YiyiFuziBaijiang Powder
Placebo group:Placebo of YiyiFuziBaijiang Powder

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically definite diagnosis of progressive colorectal adenoma, defined as an adenoma with ?>25% villous structure ,? =10 mm in diameter or with high-grade intraepithelial neoplasia, meeting one of the above criteria; 2 Age 18-75 years; 3 Chinese medicine patients with spleen deficiency and dampness, stasis and heat obstruction, who are to be treated with traditional Chinese medicine; 4 Not taking antibiotics, aspirin, immunosuppressants, etc. within three months; 5 No serious cardiac, hepatic, renal or haematopoietic diseases and other factors affecting drug evaluation; 6 Those who have a relatively stable diet, can fill in the questionnaire completely and sign the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with gastrointestinal diseases, metabolic diseases, cardiovascular diseases, liver diseases, neurological diseases and autoimmune diseases with unstable conditions and unsatisfactory control effects; 2. Taking yoghurt or probiotics regularly for a long time (2-3 times/week for more than half a year); 3. Pregnant and lactating women; 4. Allergic to a certain drug in the prescription of Chinese medicine; 5. Participants in other clinical studies; 6. Those who are considered by the investigator to be unfit to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Recurrence;

Secondary

MeasureTime frame
Chinese Medicine Symptom Score;Gastrointestinal Symptom Score;immune function;microbial diversity;metabolomics;

Countries

China

Contacts

Public ContactHua Sui

Shanghai General Hospital

syh0808@163.com+86 158 0049 2949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026